The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors
Hengmiao Cheng(Pfizer (United States)), Paul A. Rejto(Pfizer (United States)), Natilie Hosea(University of British Columbia), Stan Kupchinsky(Pfizer (United States)), Genevieve Paderes(Pfizer (United States)), Evan Walters(Pfizer (United States)), Michele Yang(Children's Hospital Colorado), Martin P. Edwards(Pfizer (United States)), Jean Matthews(Pfizer (United States)), Ganesh B. Bhat(Pfizer (United States)), Stephan J. Cripps(Pfizer (United States)), Andrea Fanjul(Pfizer (United States)), Klaus Dress(Pfizer (United States)), Jacques Ermolieff(Pfizer (United States)), Jocelyn Herrera(Pfizer (United States)), Phuong Le, Christine Loh(Ensemble Therapeutics (United States)), Jacqui Hoffman(Pfizer (United States)), Bridget Cole(Pfizer (United States)), Sajiv K. Nair(Pfizer (United States)), Tom Pauly(Pfizer (United States)), Christopher Smith(Pfizer (United States))
Cited by 44
Related Papers
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
|Nature Genetics|2011|775
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382